Home › Trial NCT05283330
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- Trial IDNCT05283330
- StatusRecruiting
- PhasePhase 1
- Study typeInterventional
- SponsorOrano Med Theranostics, SAS
- Enrollment48
- Start date2022-12-22
- ConditionsCervical Cancer · Breast Cancer · Colon Cancer · NSCLC · mCRPC (Metastatic Castration-resistant Prostate Cancer) · Glioblastoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.